Loading clinical trials...
Loading clinical trials...
Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT]
Conditions
Interventions
clinical observation
management of therapy complications
Start Date
January 1, 2006
Last Updated
December 20, 2011
NCT06337318
NCT07388563
NCT05529069
NCT05139017
NCT06263491
NCT06189391
Lead Sponsor
German High-Grade Non-Hodgkin's Lymphoma Study Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions